Ekso GT Named a Finalist in Fast Company’s 2017 World Changing Ideas Awards
March 21 2017 - 8:30AM
Ekso Bionics Holdings, Inc. (NASDAQ:EKSO), a robotic exoskeleton
company, today announced that the EksoGT has been named as a
finalist in Fast Company’s 2017 World Changing Ideas Awards.
In its premier year, the awards garnered more than 1,200
entries, and the EksoGT wearable exoskeleton was chosen from more
than 250 entries as a finalist in the Health category of this
award.
“We are honored to be selected as a finalist and
would like to thank Fast Company for recongizing Ekso Bionics,”
commented Thomas Looby, president and chief executive officer of
Ekso Bionics. “Our company was built on innovation and with the
ultimate goal of changing lives around the world with our
proprietary exoskeleton technologies.”
The EksoGT exoskeleton enables individuals who are
disabled due to stroke or spinal cord injury to stand up and walk
with a full weight bearing, reciprocal gait. Designed for the
rehabilitation setting, the EksoGT provides adaptive amounts of
power to either side of the patient’s body, allowing mobility to
patients earlier in their recovery than current standards of care
in rehabilitation. Physicians and physical therapists use
this advanced therapeutic option to help patients get back on their
feet, supporting re-learning of correct step patterns.
Utilized by over 130 rehabilitation centers around the world, the
Ekso GT has helped patients take more than 70 million steps, while
supporting patients’ hopes of early mobility and independence.
“Fast Company has always insisted that being a
force for good has to be a key element for any business,” says Fast
Company editor and managing director Robert Safian. “Companies like
Ekso Bionics, recognized for its World Changing Idea, show how
organizations around the world are embracing the ideals of
creativity and innovation to create enormous impact.”
The 2017 World Changing Ideas Awards finalists will
be highlighted in Fast Company’s April issue of their monthly
publication, which hits newsstands on March 27th.
To learn more about the EksoGT, visit
www.eksobionics.com.
About Fast CompanyFast
Company is a progressive business media brand, with an
editorial focus on innovation in technology, leadership, world
changing ideas, and design. Fast Company chronicles how
changing companies create and compete, highlighting new business
practices, and showcasing the teams and individuals who are
inventing the future and reinventing business.
World Changing Ideas is one of Fast Company’s major
annual awards programs and is focused on social good, seeking to
elevate finished products and brave concepts that make the world
better. A panel of judges from across sectors choose winners and
finalists based on feasibility and the potential for impact. With a
goal of awarding ingenuity and fostering innovation, Fast Company
draws attention to ideas with great potential and helps them expand
their reach to inspire more people to start work on solving the
problems that affect us all.
About Ekso Bionics®Ekso Bionics is
a leading developer of exoskeleton solutions that amplify human
potential by supporting or enhancing strength, endurance and
mobility across medical, industrial and defense applications.
Founded in 2005, the company continues to build upon its
unparalleled expertise to design some of the most cutting-edge,
innovative wearable robots available on the market. Ekso Bionics is
the only exoskeleton company to offer technologies that range from
helping those with paralysis to stand up and walk, to enhancing
human capabilities on job sites across the globe, to providing
research for the advancement of R&D projects intended to
benefit U.S. defense capabilities. The company is headquartered in
the Bay Area and is listed on the Nasdaq Capital Market under the
symbol EKSO. For more information, visit: www.eksobionics.com.
About Ekso GT™Ekso GT™ is the
first exoskeleton cleared by the FDA for use with stroke and spinal
cord injuries from L5 to C7. The EksoGT with SmartAssist™ software
is the only exoskeleton available for rehabilitation institutions
that can provide adaptive amounts of power to either side of the
patient’s body, challenging the patient as they progress through
their continuum of care. The suit’s patented technology provides
the ability to mobilize patients earlier, more frequently and with
a greater number of high intensity steps. To date, this device has
helped patients take more than 70 million steps in over 130
rehabilitation institutions around the world.
Forward-Looking StatementsAny
statements contained in this press release that do not describe
historical facts may constitute forward-looking statements.
Forward-looking statements may include, without limitation,
statements regarding (i) the plans and objectives of management for
future operations, including plans or objectives relating to the
design, development and commercialization of human exoskeletons,
(ii) estimates or projection of financial results, financial
condition, capital expenditures, capital structure or other
financial items, (iii) the Company's future financial performance
and (iv) the assumptions underlying or relating to any statement
described in points (i), (ii) or (iii) above. Such forward-looking
statements are not meant to predict or guarantee actual results,
performance, events or circumstances and may not be realized
because they are based upon the Company's current projections,
plans, objectives, beliefs, expectations, estimates and assumptions
and are subject to a number of risks and uncertainties and other
influences, many of which the Company has no control over. Actual
results and the timing of certain events and circumstances may
differ materially from those described by the forward-looking
statements as a result of these risks and uncertainties. Factors
that may influence or contribute to the inaccuracy of the
forward-looking statements or cause actual results to differ
materially from expected or desired results may include, without
limitation, the Company's inability to obtain adequate financing to
fund the Company's operations and necessary to develop or enhance
our technology, the significant length of time and resources
associated with the development of the Company's products, the
Company's failure to achieve broad market acceptance of the
Company's products, the failure of our sales and marketing
organization or partners to market our products effectively,
adverse results in future clinical studies of the Company's medical
device products, the failure to obtain or maintain patent
protection for the Company's technology, failure to obtain or
maintain regulatory approval to market the Company's medical
devices, lack of product diversification, existing or increased
competition, and the Company's failure to implement the Company's
business plans or strategies. These and other factors are
identified and described in more detail in the Company's filings
with the SEC. To learn more about Ekso Bionics please visit us at
www.eksobionics.com. The Company does not undertake to update these
forward-looking statements.
Media Contact:
Carrie Yamond
917-371-2320
cyamond@lazarpartners.com
Investor Contact:
Debbie Kaster
415-937-5403
investors@eksobionics.com
Ekso Bionics (NASDAQ:EKSO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ekso Bionics (NASDAQ:EKSO)
Historical Stock Chart
From Apr 2023 to Apr 2024